18F-FDG PET/CT 根据治疗后延迟时间检测头颈部鳞状细胞癌亚临床复发的诊断效能
这项单中心回顾性研究纳入 2006 年 1 月 1 日至 2021 年 12 月 31 日接受根治性治疗、每次扫描前临床检查正常的 852 例头颈部鳞状细胞癌成人患者,共完成 2,566 次 18F-FDG PET/CT。总体阳性预测值 88%、阴性预测值 98%、灵敏度 98%、特异度 89%、准确率 93%,诊断效能随时间无显著差异;检出亚临床复发 126 例(14.8%)和异时性癌 118 例(13.8%),亚临床复发检出率随时间下降、治疗后前 2 年最高。作者认为对头颈部鳞状细胞癌患者随访中常规使用 18F-FDG PET/CT 似乎合理。
要点
- 总体诊断效能:阳性预测值 88%、阴性预测值 98%、灵敏度 98%、特异度 89%、准确率 93%。
- 检出亚临床复发 126 例(14.8%)和异时性癌 118 例(13.8%)。
- 亚临床复发检出率随时间下降,治疗后前 2 年检出率最高。
核心结论
- 18F-FDG PET/CT 在头颈部鳞状细胞癌治疗后随访中检测亚临床复发具有高诊断效能,尤其是治疗后前 2 年。
- 晚期肿瘤分期、初始 PET/CT 分期上调和高体重指数与更高的亚临床复发检出可能性相关。
- 作者认为对头颈部鳞状细胞癌患者随访中常规使用 18F-FDG PET/CT 似乎合理。
研究设计与样本
- 单中心回顾性研究,纳入 2006 年 1 月 1 日至 2021 年 12 月 31 日接受根治性治疗、组织学证实为头颈部鳞状细胞癌的成人患者。
- 患者每次扫描前临床检查正常,接受强化随访策略者在治疗后 3-6 个月及此后每年一次至 5 年行静脉造影剂增强 18F-FDG PET/CT。
- 共 852 例患者完成 2,566 次 18F-FDG PET/CT,平均每人 3 次扫描。
主要发现
- 总体阳性预测值 88%、阴性预测值 98%、灵敏度 98%、特异度 89%、准确率 93%。
- 诊断效能随时间无显著差异。
- 检出亚临床复发 126 例(14.8%)和异时性癌 118 例(13.8%),亚临床复发检出率随时间下降、治疗后前 2 年最高。
- 阳性预测值随时间改善,数字 Vision 600 系统(第三期)达 90%,模拟 Gemini GXLi 系统(第一期)为 76%(P < 0.001)。
- 多因素分析确定晚期分期、高体重指数和初始 PET/CT 分期上调为亚临床复发检出的预测因素。
关键数值与推荐
- 总体诊断效能:阳性预测值 88%、阴性预测值 98%、灵敏度 98%、特异度 89%、准确率 93%。
- 亚临床复发 126 例(14.8%),异时性癌 118 例(13.8%)。
- 阳性预测值:数字 Vision 600 系统(第三期)90% vs 模拟 Gemini GXLi 系统(第一期)76%(P < 0.001)。
临床怎么用
- 作者认为对头颈部鳞状细胞癌患者随访中常规使用 18F-FDG PET/CT 似乎合理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Head and neck squamous cell carcinoma (HNSCC) remains a malignancy with high rates of locoregional recurrence and poor prognosis for recurrent cases. Early detection of subclinical lesions is challenging but critical for effective patient management. Imaging surveillance after treatment, particularly 18F-FDG PET/CT, has shown promise in the diagnosis of HNSCC recurrence. The aim was to evaluate the diagnostic performance of 18F-FDG PET/CT according to delay after treatment in detecting subclinical recurrence (SCR) in HNSCC patients. Methods: In this retrospective study, all 18F-FDG PET/CT scans were performed at a single center. All adults with histologically proven HNSCC who were treated with curative intent between January 1, 2006, and December 31, 2021, were included. They had a normal clinical examination before each scan. Patients who underwent an intensive follow-up strategy after treatment had 18F-FDG PET/CT with an intravenous contrast agent at 3-6 mo and annually thereafter for 5 y. The primary endpoint was diagnostic performance (positive and negative predictive values, sensitivity, specificity, and accuracy). Results: In total, 2,566 18F-FDG PET/CT scans were performed among 852 patients, with an average of 3 scans per patient. The overall diagnostic performance measures were as follows: positive predictive value (88%), negative predictive value (98%), sensitivity (98%), specificity (89%), and accuracy (93%). There were no significant differences in diagnostic performance over time. The scans detected 126 cases of SCR (14.8%) and 118 cases of metachronous cancer (13.8%). The incidence of SCR decreased over time, with the highest detection rate in the first 2 y after treatment. Positive predictive value improved over time, reaching 90% for the digital Vision 600 system (third period) compared with 76% for the analog Gemini GXLi system (first period, P < 0.001). Multivariate analysis identified advanced stage, high body mass index, and initial PET/CT upstaging as predictive factors for detection of SCR. Conclusion: Our study demonstrates that 18F-FDG PET/CT has high diagnostic performance in detecting SCR during follow-up after treatment of HNSCC, especially in the first 2 y. Advanced tumor stage, initial PET/CT upstaging, and high body mass index were associated with a higher likelihood of SCR detection. The routine use of 18F-FDG PET/CT during follow-up seems justified for patients with HNSCC.
引用
- Clement C, Leclère JC, Maheo C, et al. Diagnostic Performance of 18F-FDG PET/CT According to Delay After Treatment to Detect Subclinical Recurrence of Head and Neck Squamous Cell Carcinoma. J Nucl Med. 2024. PMID: 38991750. doi:10.2967/jnumed.124.267391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。